早期二甲双胍联合常规护理减少妊娠期糖尿病影响的随机安慰剂对照试验(EMERGE):研究方案
EMERGE是一项III期、优效性、平行、1:1随机、双盲、安慰剂对照试验,比较在28周(+6天)前启动二甲双胍与安慰剂联合常规护理对妊娠期糖尿病(GDM)的效果。主要复合终点为32或38周时启动胰岛素或空腹血糖≥5.1 mmol/L。试验将确定早期常规使用二甲双胍的有效性和安全性。
要点
- EMERGE为III期双盲随机安慰剂对照试验,比较早期二甲双胍联合常规护理与安慰剂联合常规护理。
- 主要复合终点为孕32或38周时启动胰岛素或空腹血糖≥5.1 mmol/L。
- 二甲双胍从500mg/天起始,10天内滴定至最大剂量2500mg。
核心结论
- EMERGE试验将确定早期和常规使用二甲双胍在GDM中的有效性和安全性。
研究设计与样本
- EMERGE为III期、优效性、平行、1:1随机、双盲、安慰剂对照试验,比较28周(+6天)前启动的二甲双胍与安慰剂联合常规护理。
- 招募18-50岁女性,排除已确诊糖尿病、多胎妊娠、已知重大先天畸形或小于胎龄儿(<第10百分位)、对二甲双胍不耐受或禁忌、休克或脓毒症、当前妊娠期高血压或子痫前期、显著胃肠道问题、充血性心力衰竭、严重精神疾病或半乳糖不耐受者。
- 干预为在医学营养治疗和常规护理基础上立即引入二甲双胍或安慰剂;二甲双胍从500mg/天起始,10天内滴定至最大剂量2500mg。
- 产后4周和12周随访评估母婴结局。
主要发现
- 主要复合终点为孕32或38周时启动胰岛素或空腹血糖≥5.1 mmol/L。
- 次要结局包括启动胰岛素的时间和所需胰岛素剂量、分娩时母亲发病率、分娩方式和时间、产后血糖状态、胰岛素抵抗、产后BMI、妊娠期增重、婴儿出生体重、新生儿身高和头围、新生儿发病率(新生儿监护病房入住、呼吸窘迫、黄疸、先天异常、Apgar评分)、新生儿低血糖、成本效果、治疗可接受性和EQ5D-5L量表评定的生活质量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregnancies affected by gestational diabetes mellitus (GDM) are associated with an increased risk of adverse maternal and foetal outcomes. Current treatments for GDM involve initial medical nutritional therapy (MNT) and exercise and pharmacotherapy in those with persistent hyperglycaemia. Insulin is considered first-line pharmacotherapy but is associated with hypoglycaemia, excessive gestational weight gain (GWG) and an increased caesarean delivery rate. Metformin is safe in selected groups of women with GDM but is not first-line therapy in many guidelines due to a lack of long-term data on efficacy. The EMERGE trial will evaluate the effectiveness of early initiation of metformin in GDM. METHODS: EMERGE is a phase III, superiority, parallel, 1:1 randomised, double-blind, placebo-controlled trial comparing the effectiveness of metformin versus placebo initiated by 28 weeks (+6 days) plus usual care. Women aged 18-50 years will be recruited. Women with established diabetes, multiple pregnancies, known major congenital malformation or small for gestational age (<10th centile), intolerance or contraindication to the use of metformin, shock or sepsis, current gestational hypertension or pre-eclampsia, significant gastrointestinal problems, congestive heart failure, severe mental illness or galactose intolerance are excluded. INTERVENTION: Immediate introduction of metformin or placebo in addition to MNT and usual care. Metformin is initiated at 500mg/day and titrated to a maximum dose of 2500mg over 10 days. Women are followed up at 4 and 12 weeks post-partum to assess maternal and neonatal outcomes. The composite primary outcome measure is initiation of insulin or fasting blood glucose ≥ 5.1 mmol/L at gestational weeks 32 or 38. The secondary outcomes are the time to insulin initiation and insulin dose required; maternal morbidity at delivery; mode and time of delivery; postpartum glucose status; insulin resistance; postpartum body mass index (BMI); gestational weight gain; infant birth weight; neonatal height and head circumference at delivery; neonatal morbidities (neonatal care unit admission, respiratory distress, jaundice, congenital anomalies, Apgar score); neonatal hypoglycaemia; cost-effectiveness; treatment acceptability and quality of life determined by the EQ5D-5L scale. DISCUSSION: The EMERGE trial will determine the effectiveness and safety of early and routine use of metformin in GDM. TRIAL REGISTRATION: EudraCT Number 2016-001644-19l; NCT NCT02980276 . Registered on 6 June 2017.
引用
- Dunne F, Newman C, Devane D, et al. A randomised placebo-controlled trial of the effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects (EMERGE): study protocol. Trials. 2022. PMID: 36131291. doi:10.1186/s13063-022-06694-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。